Search
Relutrigine
go.drugbank.com/drugs/DB21614InvestigationalRelutrigine has a monoisotopic molecular weight of 407.08 Da. … Relutrigine is a small molecule drug. The usage of the INN stem '-trigine' in the name indicates that Relutrigine is a sodium channel blocker, signal transduction modulator.
αAβ–Gas6
go.drugbank.com/drugs/DB17069ExperimentalαAβ–Gas6 is a chimeric fusion protein being investigated in preclinical studies as an immunotherapeutic agent for Alzheimer's disease (AD). … [A253203,A253208] αAβ–Gas6 is a phagocyte inducer of Aβ,[A253203] which is the main component of the amyloid plaques found in individuals with AD and is considered to contribute to the pathophysiology
Quinaprilat
go.drugbank.com/drugs/DB14217ExperimentalThe active metabolite of the prodrug quinapril.
Categories: Agents Acting on the Renin-Angiotensin SystemNizubaglustat
go.drugbank.com/drugs/DB21603InvestigationalNizubaglustat has a monoisotopic molecular weight of 433.23 Da. … Nizubaglustat is a small molecule drug. The usage of the INN stem '-glustat' in the name indicates that Nizubaglustat is a ceramide glucosyltransferase inhibitor.
Nevadistinel
go.drugbank.com/drugs/DB21632InvestigationalNevadistinel is a small molecule drug. The usage of the INN stem '-stinel' in the name indicates that Nevadistinel is a N-methyl-D-aspartate (NMDA) receptor co-agonist. … Nevadistinel has a monoisotopic molecular weight of 274.13 Da.
Flizasertib
go.drugbank.com/drugs/DB21613InvestigationalFlizasertib has a monoisotopic molecular weight of 271.11 Da. … Flizasertib is a small molecule drug. The usage of the INN stem '-sertib' in the name indicates that Flizasertib is a serine/threonine kinase inhibitor.
Zibrofusidic acid
go.drugbank.com/drugs/DB20799InvestigationalZibrofusidic acid has a monoisotopic molecular weight of 594.26 Da. … Zibrofusidic acid is a small molecule drug.
Evixapodlin
go.drugbank.com/drugs/DB21520InvestigationalEvixapodlin has a monoisotopic molecular weight of 690.22 Da. … Evixapodlin is a small molecule drug.
Apronalide
go.drugbank.com/drugs/DB13221ApprovedApronalide is approved in Japan. Apronalide has been withdrawn from the market in many other countries due to patient development of thrombocytopenic purpura [A174814].